EGFR and neoplasm: Previous studies have shown that patients with advanced NSCLC carrying EGFR mutations have a poor response to immunotherapy, and a possible mechanism for this poor response is the low expression of PD-L1 or the lack of infiltrating T cells in the tumor microenvironment (TME) (11–14).